Loading…
← CockpitCompetitor Analysis › NEULANDLAB.NS Neuland LaboratoriesOpen in the cockpit ↗

Neuland LaboratoriesNEULANDLAB.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Manufactures active pharmaceutical ingredients (APIs) and offers contract development/manufacturing services to global pharma companies.

≈ A mid-sized Indian API/CDMO playerMomentum strong 74
Mkt cap
$2.95B
US dollars, full cap
Free float
56%
of shares outstanding
$/day
$12.8M
20-day average traded
Fwd P/E
63.4×
forward earnings
ROIC−WACC
+6.9 pp
WACC 16.4%
Hurdle
n/a
no reverse DCF
Next earnings
89 days
15 Feb 2027
Close · INR₹21,455
1D+0.1%
1W+6.2%
1M+11.6%
3M-8.2%
6M+27.8%
YTD+41.4%
1Y+22.1%
ATR %3.6%
Beta0.76
52w lowhigh11.4% off high

What Neuland Laboratories does

Manufactures active pharmaceutical ingredients (APIs) and offers contract development/manufacturing services to global pharma companies.

Sells generic active ingredients (the part of a medicine that works) in volume to generic drugmakers, where customers qualify the plant and product before ordering, and does custom synthesis under contract for innovator companies at higher value. The founding family leads the company.

In one line: A mid-sized Indian API/CDMO player.

Products and services

  • Generic APIs
  • Custom manufacturing/CDMO
  • Specialty/peptide APIs

Customers

  • Global generic drug makers
  • Innovator pharma companies (CDMO contracts)

Where it sits in the supply chain

  • Chemical synthesis R&D
  • API manufacturing
  • CDMO services for global pharma

What could go right

  • Global API outsourcing to India
  • CDMO contract wins

What could go wrong

  • Raw material/solvent cost volatility
  • Customer concentration in CDMO deals

Moat: narrow (regulatory licence, process know-how). US FDA/EU-approved API plants and chemistry expertise support long-term supply contracts.

Headquarters: Hyderabad, India · Founded: 1984 · Employees: 3,881

Named competitors

Neuland Laboratories at a glance

Size Neuland Laboratories (NEULANDLAB.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $2.95B, the 296th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹21,455 on 18 Nov 2026.

Performance Over six months the shares gained 27.8%, against -8.4% for the median peer and +3.8% for the India market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 50.5% over the last twelve months (peer median +9.4%); the operating margin is 26.0% (peer median 11.3%).

Valuation It trades at 63.4× forward earnings against a peer median of 22.1× (3rd most expensive of 17).

Capital Return on invested capital runs 6.9 points above its cost of capital (16.4% WACC).

Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026NEULANDLAB.NS 129Peer median 91
Six months, rebased to 100: Neuland Laboratories against the median of its 20 peers (local-currency closes).

Neuland Laboratories financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹23.1B₹20.0B₹14.5B₹15.3B₹11.8B
Revenue growth—+37%-5%+31%—
Gross profit₹7.65B₹6.33B₹3.82B₹4.99B₹3.07B
EBITDA₹7.05B₹5.61B₹3.12B₹4.46B₹2.69B
Net income₹4.53B₹3.64B₹2.60B₹3.00B₹1.64B
Free cash flown/a-₹589M₹1.13B₹1.12B₹1.60B
Capital expendituren/a₹3.97B₹2.06B₹1.44B₹661M
Total debt₹3.42B₹3.01B₹1.57B₹954M₹1.28B

Quarterly statements and history in the cockpit →

Neuland Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%-20%0%+20%0867002773VCEL6003802696ACADLEGN688266600535300558300199BIOA-B600518000739IDYAPPLPHARMAVRDNNEULANDLAB.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Neuland Laboratories is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%+100%+150%0×50×100×150×0867002773VCEL6003802696LEGN688266300558300199BIOA-B000739PPLPHARMA2096NEULANDLAB.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Neuland Laboratories is the large dot.

Neuland Laboratories competitors and peer comparison

Head to head with its named competitors (NEULANDLAB.NS vs DIVISLAB.NS vs LAURUSLABS.NS vs PPLPHARMA.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Neuland Laboratories NEULANDLAB.NS$2.95B+28%+50%26%63.4×n/a
Divi's Laboratories DIVISLAB.NS$31.3B+60%+22%34%73.5×47.1%
Laurus Labs LAURUSLABS.NS$13.4B+73%+23%24%76.4×51.2%
Piramal Pharma PPLPHARMA.NS$3.40B+38%+9%3%150.8×n/a

How Neuland Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Neuland Laboratories against its 20 peers (data as of 18 Nov 2026)
MeasureNEULANDLAB.NSPeer medianRank in peer set
1-month return+11.6%-1.4%5th highest of 21
6-month return+27.8%-8.4%4th highest of 21
Distance from 52-week high-11.4%-34.8%4th highest of 21
Revenue growth (TTM)+50.5%+9.4%3rd highest of 20
Operating margin26.0%11.3%3rd highest of 20
Forward P/E63.4×22.1×3rd most expensive of 17
ROIC minus cost of capital+6.9 pp+1.4 pp6th highest of 17
EV / EBITDA38.9×18.7×2nd most expensive of 8
Net debt / EBITDA-0.1×-1.9×3rd most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Neuland Laboratories NEULANDLAB.NSIndia$2.95B+28%+50%26%63.4×n/an/a
China Medical System 0867.HKHong Kong$2.95B-15%+15%20%9.8×1.1%+2.7%
Chengdu Kanghong Pharmaceutical 002773.SZChina$2.99B-1%-11%24%20.1×-3.3%+7.0%
Vericel VCELUnited States$2.99B+66%+25%8%68.3×46.5%+17.3%
Joincare Pharmaceutical Group Industry 600380.SSChina$2.85B0%-12%18%15.5×-13.1%+2.4%
Shanghai Henlius Biotech 2696.HKHong Kong$3.05B-39%+33%12%21.3×14.1%+61.4%
ACADIA Pharmaceuticals ACADUnited States$3.08B-15%+15%10%17.8×9.2%+19.4%
Legend Biotech Corp. Sponsored ADR LEGNUnited States$3.12B-42%+50%3%34.2×n/an/a
Suzhou Zelgen Biopharmaceuticals 688266.SSChina$3.13B-25%+136%29%36.1×17.7%+98.4%
Tasly Pharmaceutical 600535.SSChina$3.19B-2%-4%19%16.7×-7.5%-9.6%
Betta Pharmaceuticals 300558.SZChina$2.70B-15%+16%11%38.0×23.2%+14.0%
Hybio Pharmaceutical 300199.SZChina$2.68B-8%+70%31%44.7×37.4%+6.1%
China National Medicines 600511.SSChina$3.26B+3%+3%4%10.5×-10.0%+5.4%
BioArctic BIOA-B.STSweden$2.66B-9%-46%22%52.9×25.5%+100.1%
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%n/an/an/a
Viking Therapeutics VKTXUnited States$3.34B-9%n/an/an/an/an/a
Apeloa Pharmaceutical 000739.SZChina$3.37B+17%-16%10%22.9×4.7%+4.5%
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%n/an/an/a
Piramal Pharma PPLPHARMA.NSIndia$3.40B+38%+9%3%150.8×n/an/a
Simcere Pharmaceutical 2096.HKHong Kong$3.42B-5%+27%18%13.5×-3.4%+10.6%
Viridian Therapeutics VRDNUnited States$3.42B+71%-63%-1,781%n/an/an/a

Questions

Who are Neuland Laboratories's main competitors?
Named competitors: Divi's Laboratories (DIVISLAB.NS), Laurus Labs (LAURUSLABS.NS), Piramal Pharma (PPLPHARMA.NS). The cockpit's measured peer set (industry) also includes China Medical System (0867.HK), Chengdu Kanghong Pharmaceutical (002773.SZ), Vericel (VCEL), Joincare Pharmaceutical Group Industry (600380.SS), Shanghai Henlius Biotech (2696.HK), ACADIA Pharmaceuticals (ACAD).
Is Neuland Laboratories expensive compared with its peers?
On forward p/e it trades at 63.4× against a peer median of 22.1×, 3rd most expensive of 17 in its peer set.
How has Neuland Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned +27.8% against -8.4% for the median peer; over one year +22.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.